Screener
BioCryst Pharmaceuticals BCRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's cash & equivalents?
- BioCryst Pharmaceuticals (BCRX) reported cash & equivalents of $156.38M in Q2 2026.
- How has BioCryst Pharmaceuticals's cash & equivalents changed year-over-year?
- BioCryst Pharmaceuticals's cash & equivalents increased by 73.9% year-over-year, from $89.93M to $156.38M.
- What is the long-term trend for BioCryst Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's cash & equivalents has grown at a -19.6% compound annual growth rate (CAGR), from $272.13M to $91.34M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about BioCryst Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude